Quizartinib [6], crenolanib [7] and gilteritinib [8] are 2nd generation FLT3 inhibitors (FLT3i) in phase III trials or clinical use for the targeted treatment of FLT3-ITD + AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.